Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 204 articles: HTML format

Single Articles

July 2021
1. LUO J, Martucci VL, Quandt Z, Groha S, et al
   Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
   Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
   PubMed     Abstract available
   
   
   June 2021
2. WEISS SA, Djureinovic D, Jessel S, Krykbaeva I, et al
   A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.
   Clin Cancer Res. 2021 Jun 17. pii: 1078-0432.CCR-21-0903.
   PubMed     Abstract available
   
   
   
3. GARON EB, Spira AI, Johnson M, Bazhenova L, et al
   A phase 1b open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung cancer.
   Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0263.
   PubMed     Abstract available
   
   
   May 2021
4. CORTOT AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, et al
   First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
   Clin Cancer Res. 2021 May 24. pii: 1078-0432.CCR-20-4604.
   PubMed     Abstract available
   
   
   
5. BYERS LA, Bentsion D, Gans S, Penkov K, et al
   Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
   Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-20-4259.
   PubMed     Abstract available
   
   
   April 2021
6. SHAFIQUE M, Fisher TL, Evans EE, Leonard JE, et al
   A Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.
   Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4792.
   PubMed     Abstract available
   
   
   March 2021
7. LIN JJ, Choudhury NJ, Yoda S, Zhu VW, et al
   Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
   Clin Cancer Res. 2021 Mar 8. pii: 1078-0432.CCR-21-0032.
   PubMed     Abstract available
   
   
   February 2021
8. VELLANKI PJ, Mulkey F, Jaigirdar AA, Rodriguez L, et al
   FDA Approval Summary: Nivolumab with Ipilimumab and Chemotherapy for Metastatic Non-Small Cell Lung Cancer, a Collaborative Project Orbis Review.
   Clin Cancer Res. 2021 Feb 25. pii: 1078-0432.CCR-20-4338.
   PubMed     Abstract available
   
   
   
9. DATAR IJ, Hauc S, Desai SS, Gianino N, et al
   Spatial analysis and clinical significance of HLA class-I and class-II subunit expression in non-small cell lung cancer.
   Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-3655.
   PubMed     Abstract available
   
   
   
10. SKWARSKI M, McGowan DR, Belcher E, Di Chiara F, et al
    Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 17. pii: 1078-0432.CCR-20-4128.
    PubMed     Abstract available
    
    
    
11. HARVEY RD, Bruinooge SS, Chen L, Garrett-Mayer E, et al
    Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations.
    Clin Cancer Res. 2021 Feb 9. pii: 1078-0432.CCR-20-3857.
    PubMed     Abstract available
    
    
    
12. ARBOUR KC, Rizvi H, Plodkowski AJ, Hellmann MD, et al
    Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-4023.
    PubMed     Abstract available
    
    
    December 2020
13. SINGH S, Jaigirdar AA, Mulkey F, Cheng J, et al
    FDA Approval Summary: Lurbinectedin for the Treatment of Metastatic Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Dec 7. pii: 1078-0432.CCR-20-3901.
    PubMed     Abstract available
    
    
    
14. DE HAAN R, Van den Heuvel M, van Diessen J, Peulen HMU, et al
    Phase 1 and pharmacological study of olaparib in combination with high-dose radiotherapy with and without concurrent cisplatin for non-small cell lung cancer.
    Clin Cancer Res. 2020 Dec 1. pii: 1078-0432.CCR-20-2551.
    PubMed     Abstract available
    
    
    November 2020
15. GIFFIN MJ, Cooke K, Lobenhofer EK, Estrada JC, et al
    AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Nov 17. pii: 1078-0432.CCR-20-2845.
    PubMed     Abstract available
    
    
    
16. SALAS-BENITO D, Eguren-Santamaria I, Sanmamed MF
    Senescent T-cells as a resistance mechanism to lung cancer immunotherapy.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3507.
    PubMed     Abstract available
    
    
    October 2020
17. ROSEN EY, Johnson ML, Clifford SE, Somwar R, et al
    Overcoming MET-dependent resistance to selective RET inhibition in patients with RET fusion-positive lung cancer by combining selpercatinib with crizotinib.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-2278.
    PubMed     Abstract available
    
    
    
18. SINGH A, Daemen A, Nickles D, Jeon SM, et al
    NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes.
    Clin Cancer Res. 2020 Oct 19. pii: 1078-0432.CCR-20-1985.
    PubMed     Abstract available
    
    
    
19. YU HA, Paz-Ares LG, Yang JC, Lee KH, et al
    Phase 1 Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Oct 12. pii: 1078-0432.CCR-20-1690.
    PubMed     Abstract available
    
    
    September 2020
20. ADACHI Y, Ito K, Hayashi Y, Kimura R, et al
    Epithelial to mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant non-small cell lung cancer.
    Clin Cancer Res. 2020 Sep 8. pii: 1078-0432.CCR-20-2077.
    PubMed     Abstract available
    
    
    
21. FERRARA R, Naigeon M, Auclin E, Duchemann B, et al
    Circulating T-cell immunosenescence in advanced non-small cell lung cancer patients treated with single agent PD-1/PD-L1 inhibitors or platinum-based chemotherapy.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1420.
    PubMed     Abstract available
    
    
    August 2020
22. ORTIZ-CUARAN S, Mezquita L, Swalduz A, Aldea M, et al
    Circulating tumor DNA genomics reveals potential mechanisms of resistance to BRAF-targeted therapies in BRAF-mutant metastatic non-small cell lung cancer patients.
    Clin Cancer Res. 2020 Aug 28. pii: 1078-0432.CCR-20-1037.
    PubMed     Abstract available
    
    
    
23. GERBER DE, Putnam WC, Fattah FJ, Kernstine KH, et al
    Concentration-dependent early anti-vascular and anti-tumor effects of itraconazole in non-small cell lung cancer.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-1916.
    PubMed     Abstract available
    
    
    
24. XING L, Pan Y, Shi Y, Shu Y, et al
    Biomarkers of osimertinib response in patients with refractory, EGFR-T790M-positive non-small cell lung cancer and central nervous system metastases:the APOLLO study.
    Clin Cancer Res. 2020 Aug 17. pii: 1078-0432.CCR-20-2081.
    PubMed     Abstract available
    
    
    July 2020
25. MADAJEWSKI B, Chen F, Yoo B, Turker MZ, et al
    Molecular Engineering of Ultrasmall Silica Nanoparticle-Drug Conjugates as Lung Cancer Therapeutics.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0851.
    PubMed     Abstract available
    
    
    
26. SCHOENFELD AJ, Bandlamudi C, Lavery JA, Montecalvo J, et al
    The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer.
    Clin Cancer Res. 2020 Jul 24. pii: 1078-0432.CCR-20-1825.
    PubMed     Abstract available
    
    
    
27. BLAKELY CM, McCoach CE
    Role of MPR as an Early Signal for Efficacy in Neoadjuvant Studies.
    Clin Cancer Res. 2020;26:3499-3500.
    PubMed     Abstract available
    
    
    
28. MULLER M, Hummelink K, Hurkmans DP, Niemeijer AN, et al
    A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors.
    Clin Cancer Res. 2020 Jul 6. pii: 1078-0432.CCR-20-0538.
    PubMed     Abstract available
    
    
    
29. AGGARWAL C, Thompson JC, Carpenter EL
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Response.
    Clin Cancer Res. 2020;26:3492.
    PubMed    
    
    
    
30. LI X, Xu Y, Wang G, Li L, et al
    Plasma Tumor Mutation Burden and Response to Pembrolizumab-Letter.
    Clin Cancer Res. 2020;26:3491.
    PubMed    
    
    
    
31. GOERIG NL, Frey B, Korn K, Fleckenstein B, et al
    Early Mortality of Brain Cancer Patients and its Connection to Cytomegalovirus Reactivation During Radiochemotherapy.
    Clin Cancer Res. 2020;26:3259-3270.
    PubMed     Abstract available
    
    
    June 2020
32. HIPP S, Voynov V, Drobits-Handl B, Giragossian C, et al
    A Bispecific DLL3/CD3 IgG-like T-cell Antibody induces anti-tumor responses in Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Jun 18. pii: 1078-0432.CCR-20-0926.
    PubMed     Abstract available
    
    
    
33. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Correction: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:2768.
    PubMed    
    
    
    
34. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Correction: Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:2767.
    PubMed    
    
    
    
35. PIOTROWSKA Z, Hata AN
    Resistance to First-line Osimertinib in EGFR-mutant NSCLC: Tissue is the Issue.
    Clin Cancer Res. 2020;26:2441-2443.
    PubMed     Abstract available
    
    
    May 2020
36. LIU B, Ricarte-Filho J, Mallisetty A, Villani C, et al
    Detection of promoter DNA methylation in urine and plasma aids the detection of non-small cell lung cancer.
    Clin Cancer Res. 2020 May 19. pii: 1078-0432.CCR-19-2896.
    PubMed     Abstract available
    
    
    
37. BAGLEY SJ, Carpenter EL
    Plasma cfDNA in Glioblastoma-Response.
    Clin Cancer Res. 2020;26:2276.
    PubMed    
    
    
    
38. GLITZA OLIVA IC, Tawbi HA
    "Liquid Gold" - The unTAPped Potential of Cerebrospinal Fluid Analysis?
    Clin Cancer Res. 2020;26:2083-2084.
    PubMed     Abstract available
    
    
    April 2020
39. RICCIUTI B, Recondo G, Spurr LF, Li YY, et al
    Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer.
    Clin Cancer Res. 2020 Apr 24. pii: 1078-0432.CCR-19-3529.
    PubMed     Abstract available
    
    
    
40. COOPER AJ, Kobayashi Y, Kim D, Clifford SE, et al
    Identification of a RAS-activating TMEM87A-RASGRF1 fusion in an exceptional responder to sunitinib with non-small cell lung cancer.
    Clin Cancer Res. 2020 Apr 20. pii: 1078-0432.CCR-20-0397.
    PubMed     Abstract available
    
    
    
41. PAIK PK, Kim RK, Ahn L, Plodkowski AJ, et al
    A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers.
    Clin Cancer Res. 2020;26:1796-1802.
    PubMed     Abstract available
    
    
    
42. YUN MR, Kim DH, Kim SY, Joo HS, et al
    Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Apr 8. pii: 1078-0432.CCR-19-2777.
    PubMed     Abstract available
    
    
    
43. ZUGAZAGOITIA J, Gupta S, Liu Y, Fuhrman K, et al
    Biomarkers associated with beneficial PD-1 checkpoint blockade in non-small-cell lung cancer (NSCLC) identified using high-plex digital spatial profiling.
    Clin Cancer Res. 2020 Apr 6. pii: 1078-0432.CCR-20-0175.
    PubMed     Abstract available
    
    
    
44. VAN DEN BROECK A, Brambilla E, Moro-Sibilot D, Lantuejoul S, et al
    Editor's Note: Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020;26:1776.
    PubMed    
    
    
    
45. LANDI L, Bruno R, Fontanini G, Cappuzzo F, et al
    Crizotinib in ROS1 and MET Deregulated NSCLC-Response.
    Clin Cancer Res. 2020;26:1775.
    PubMed    
    
    
    
46. WIESWEG M, Schuler M, Schildhaus HU
    Crizotinib in ROS1 and MET Deregulated NSCLC-Letter.
    Clin Cancer Res. 2020;26:1774.
    PubMed    
    
    
    
47. YAEGER R, Solit DB
    Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting.
    Clin Cancer Res. 2020;26:1538-1540.
    PubMed     Abstract available
    
    
    March 2020
48. DERCLE L, Fronheiser M, Lu L, Du S, et al
    Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
    Clin Cancer Res. 2020 Mar 20. pii: 1078-0432.CCR-19-2942.
    PubMed     Abstract available
    
    
    
49. CASCONE T, Sepesi B, Lin H, Kalhor N, et al
    A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2020 Mar 19. pii: 1078-0432.CCR-19-4180.
    PubMed     Abstract available
    
    
    
50. HENICK BS
    Elite Intratumoral T-cell Clonotypes (The 1%) Effect "Trickle-Down Cytotoxicity".
    Clin Cancer Res. 2020;26:1205-1207.
    PubMed     Abstract available
    
    
    
51. CHUNG JS, Ramani V, Kobayashi M, Fattah F, et al
    DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Clin Cancer Res. 2020;26:1449-1459.
    PubMed     Abstract available
    
    
    
52. HSIAO TF, Wang CL, Wu YC, Feng HP, et al
    Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer.
    Clin Cancer Res. 2020 Mar 10. pii: 1078-0432.CCR-19-3972.
    PubMed     Abstract available
    
    
    February 2020
53. AGGARWAL C, Thompson JC, Chien AL, Quinn KJ, et al
    Baseline plasma tumor mutation burden predicts response to pembrolizumab-based therapy in patients with metastatic non-small cell lung cancer.
    Clin Cancer Res. 2020 Feb 26. pii: 1078-0432.CCR-19-3663.
    PubMed     Abstract available
    
    
    
54. DAGOGO-JACK I, Yoda S, Lennerz JK, Langenbucher A, et al
    MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
    Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-19-3906.
    PubMed     Abstract available
    
    
    
55. HOPKINS AM, Kichenadasse G, Garrett-Mayer E, Karapetis CS, et al
    Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab.
    Clin Cancer Res. 2020 Feb 21. pii: 1078-0432.CCR-19-2968.
    PubMed     Abstract available
    
    
    
56. ZHUO M, Guan Y, Yang X, Hong L, et al
    The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
    Clin Cancer Res. 2020;26:892-901.
    PubMed     Abstract available
    
    
    
57. LIU Y, Zugazagoitia J, Ahmed FS, Henick BS, et al
    Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy.
    Clin Cancer Res. 2020;26:970-977.
    PubMed     Abstract available
    
    
    
58. LI X, Zhang L, Jiang D, Wang Y, et al
    Routine-dose and High-dose Icotinib in Advanced Non-Small Cell Lung Cancer Patients harboring EGFR Exon 21 L858R Mutation: the Randomized, Phase II, INCREASE Trial.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-3064.
    PubMed     Abstract available
    
    
    
59. IVANOVA E, Kuraguchi M, Xu M, Portell A, et al
    Use of ex vivo patient derived tumor organotypic spheroids to identify combination therapies for HER2mutant non small cell lung cancer.
    Clin Cancer Res. 2020 Feb 7. pii: 1078-0432.CCR-19-1844.
    PubMed     Abstract available
    
    
    January 2020
60. FRICK MA, Feigenberg SJ, Jean-Baptiste SR, Aguarin LA, et al
    Circulating tumor cells are associated with recurrent disease in patients with early stage non-small cell lung cancer treated with stereotactic body radiation therapy.
    Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-2158.
    PubMed     Abstract available
    
    
    
61. OKURA N, Nishioka N, Yamada T, Taniguchi H, et al
    ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2321.
    PubMed     Abstract available
    
    
    
62. POCHA K, Mock A, Rapp C, Dettling S, et al
    Surfactant expression defines an inflamed subtype of lung adenocarcinoma brain metastases that correlates with prolonged survival.
    Clin Cancer Res. 2020 Jan 17. pii: 1078-0432.CCR-19-2184.
    PubMed     Abstract available
    
    
    
63. DI FEDERICO A, Filippini DM, Dall'Olio FG, Conci N, et al
    The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.
    Clin Cancer Res. 2020;26:518-519.
    PubMed    
    
    
    
64. ISOMOTO K, Haratani K, Hayashi H, Shimizu S, et al
    Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer.
    Clin Cancer Res. 2020 Jan 14. pii: 1078-0432.CCR-19-2027.
    PubMed     Abstract available
    
    
    
65. SCHOENFELD AJ, Chan JM, Kubota D, Sato H, et al
    Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.
    Clin Cancer Res. 2020 Jan 7. pii: 1078-0432.CCR-19-3563.
    PubMed     Abstract available
    
    
    
66. KIM BH, Kim YJ, Kim MH, Na YR, et al
    Identification of FES as a Novel Radiosensitizing Target in Human Cancers.
    Clin Cancer Res. 2020;26:265-273.
    PubMed     Abstract available
    
    
    November 2019
67. TAMMINGA M, de Wit S, Van De Wauwer C, van den Bos H, et al
    Release of circulating tumor cells during surgery for non-small cell lung cancer: are they what they appear to be?
    Clin Cancer Res. 2019 Nov 26. pii: 1078-0432.CCR-19-2541.
    PubMed     Abstract available
    
    
    
68. ZHANG J, Ji Z, Caushi JX, El Asmar M, et al
    Compartmental analysis of T cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 21. pii: 1078-0432.CCR-19-2931.
    PubMed     Abstract available
    
    
    
69. DIZIER B, Callegaro A, Debois M, Dreno B, et al
    A T-helper 1/interferon- gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 15. pii: 1078-0432.CCR-18-3717.
    PubMed     Abstract available
    
    
    
70. SHI R, Radulovich N, Ng C, Liu N, et al
    Organoid cultures as preclinical models of non-small cell lung cancer.
    Clin Cancer Res. 2019 Nov 6. pii: 1078-0432.CCR-19-1376.
    PubMed     Abstract available
    
    
    October 2019
71. BLAKELY CM
    A new pathway emerges to interpret lung cancer genomic alterations.
    Clin Cancer Res. 2019 Oct 14. pii: 1078-0432.CCR-19-2861.
    PubMed     Abstract available
    
    
    
72. RECONDO G, Mezquita L, Facchinetti F, Planchard D, et al
    Diverse resistance mechanisms to the third-generation ALK inhibitor lorlatinib in ALK-rearranged lung cancer.
    Clin Cancer Res. 2019 Oct 4. pii: 1078-0432.CCR-19-1104.
    PubMed     Abstract available
    
    
    
73. YANG Y, Yang H, Tang B, Wu AML, et al
    The outcome of TGFbeta antagonism in metastatic breast cancer models in vivo reflects a complex balance between tumor-suppressive and pro-progression activities of TGFbeta.
    Clin Cancer Res. 2019 Oct 3. pii: 1078-0432.CCR-19-2370.
    PubMed     Abstract available
    
    
    September 2019
74. JEONG Y, Hellyer JA, Stehr H, Hoang NT, et al
    Role of KEAP1/NFE2L2 mutations in the chemotherapeutic response of non-small cell lung cancer patients.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1237.
    PubMed     Abstract available
    
    
    
75. ROTOW JK, Gui P, Wu W, Raymond VM, et al
    Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.
    Clin Cancer Res. 2019 Sep 23. pii: 1078-0432.CCR-19-1667.
    PubMed     Abstract available
    
    
    
76. GERBER DE, Infante JR, Gordon MS, Goldberg SB, et al
    Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer Patients.
    Clin Cancer Res. 2019 Sep 20. pii: 1078-0432.CCR-18-3965.
    PubMed     Abstract available
    
    
    
77. MANSFIELD AS, Zauderer MG
    Nivo-lution in Mesothelioma.
    Clin Cancer Res. 2019;25:5438-5440.
    PubMed     Abstract available
    
    
    
78. MORGENSZTERN D, Besse B, Greillier L, Santana-Davila R, et al
    Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Clin Cancer Res. 2019 Sep 10. pii: 1078-0432.CCR-19-1133.
    PubMed     Abstract available
    
    
    August 2019
79. WANG W, Huang L, Jin JY, Pi W, et al
    A Validation Study on IDO Immune Biomarkers for Survival Prediction in Non-small Cell Lung Cancer: Radiation Dose Fractionation Effect in Early Stage Disease.
    Clin Cancer Res. 2019 Aug 30. pii: 1078-0432.CCR-19-1202.
    PubMed     Abstract available
    
    
    
80. CHANG JC, Alex D, Bott M, Tan KS, et al
    Comprehensive next-generation sequencing unambiguously distinguishes separate primary lung carcinomas from intra-pulmonary metastases: Comparison with standard histopathologic approach.
    Clin Cancer Res. 2019 Aug 30. pii: 1078-0432.CCR-19-1700.
    PubMed     Abstract available
    
    
    
81. PAILLER E, Faugeroux V, Oulhen M, Mezquita L, et al
    Acquired Resistance Mutations to ALK-Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-1176.
    PubMed     Abstract available
    
    
    
82. CHEN K, Zhao H, Shi Y, Yang F, et al
    Perioperative dynamic changes in circulating tumor DNA in lung cancer patients (DYNAMIC).
    Clin Cancer Res. 2019 Aug 22. pii: 1078-0432.CCR-19-1213.
    PubMed     Abstract available
    
    
    
83. LANDI L, Chiari R, Tiseo M, D'Inca F, et al
    Crizotinib in MET deregulated or ROS1 rearranged pretreated non-small-cell lung cancer (METROS): a phase II, prospective, multicentre, two-arms trial.
    Clin Cancer Res. 2019 Aug 15. pii: 1078-0432.CCR-19-0994.
    PubMed     Abstract available
    
    
    
84. JONNA S, Feldman RA, Swensen J, Gatalica Z, et al
    Detection of NRG1 Gene Fusions in Solid Tumors.
    Clin Cancer Res. 2019;25:4966-4972.
    PubMed     Abstract available
    
    
    
85. GRAY JE, Saltos AN, Tanvetyanon T, Haura EB, et al
    Phase 1/1b study of pembrolizumab plus vorinostat in advanced/metastatic non-small cell lung cancer.
    Clin Cancer Res. 2019 Aug 13. pii: 1078-0432.CCR-19-1305.
    PubMed     Abstract available
    
    
    
86. ISHIZAWA K, Yamanaka M, Saiki Y, Miyauchi E, et al
    CD45+CD326+ Cells are predictive of poor prognosis in Non-Small Cell Lung Cancer patients.
    Clin Cancer Res. 2019 Aug 5. pii: 1078-0432.CCR-19-0545.
    PubMed     Abstract available
    
    
    
87. JONES MR, Williamson LM, Topham JT, Lee MKC, et al
    NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma.
    Clin Cancer Res. 2019;25:4674-4681.
    PubMed     Abstract available
    
    
    
88. BENAYED R, Offin M, Mullaney K, Sukhadia P, et al
    High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden.
    Clin Cancer Res. 2019;25:4712-4722.
    PubMed     Abstract available
    
    
    July 2019
89. DEVARAKONDA S, Sankararaman S, Herzog B, Gold KA, et al
    Circulating Tumor DNA Profiling in Small Cell Lung Cancer Identifies Potentially Targetable Alterations.
    Clin Cancer Res. 2019 Jul 12. pii: 1078-0432.CCR-19-0879.
    PubMed     Abstract available
    
    
    June 2019
90. CHALISHAZAR MD, Wait SJ, Huang F, Ireland AS, et al
    MYC-driven small cell lung cancer is metabolically distinct and vulnerable to arginine depletion.
    Clin Cancer Res. 2019 Jun 4. pii: 1078-0432.CCR-18-4140.
    PubMed     Abstract available
    
    
    May 2019
91. SU Z, Wang Z, Ni X, Duan J, et al
    Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-3571.
    PubMed     Abstract available
    
    
    
92. HU-LIESKOVAN S, Lisberg A, Zaretsky JM, Grogan TR, et al
    Tumor characteristics associated with benefit from pembrolizumab in advanced non-small cell lung cancer.
    Clin Cancer Res. 2019 May 21. pii: 1078-0432.CCR-18-4275.
    PubMed     Abstract available
    
    
    
93. THATCHER N, Goldschmidt JH, Thomas M, Schenker M, et al
    Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
    Clin Cancer Res. 2019;25:3193.
    PubMed    
    
    
    
94. DAGOGO-JACK I, Awad MM, Shaw AT
    BRAF Mutation Class and Clinical Outcomes-Response.
    Clin Cancer Res. 2019;25:3189.
    PubMed    
    
    
    
95. DANKNER M, Rose AAN
    BRAF Mutation Class and Clinical Outcomes-Letter.
    Clin Cancer Res. 2019;25:3188.
    PubMed    
    
    
    
96. FANG W, Ma Y, Yin JC, Hong S, et al
    Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small-Cell Lung Cancer.
    Clin Cancer Res. 2019 May 13. pii: 1078-0432.CCR-19-0585.
    PubMed     Abstract available
    
    
    
97. DATAR IJ, Sanmamed MF, Wang J, Henick BS, et al
    Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
    Clin Cancer Res. 2019 May 3. pii: 1078-0432.CCR-18-4142.
    PubMed     Abstract available
    
    
    
98. SALEM A, Little RA, Latif A, Featherstone AK, et al
    Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer.
    Clin Cancer Res. 2019 May 3. pii: 1078-0432.CCR-18-3932.
    PubMed     Abstract available
    
    
    April 2019
99. XU Y, Hosny A, Zeleznik R, Parmar C, et al
    Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-2495.
    PubMed     Abstract available
    
    
    
100. ZHANG J, Chen J, Wo D, Yan H, et al
     LRP6 ectodomain prevents SDF-1/CXCR4-induced breast cancer metastasis to lung.
     Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3557.
     PubMed     Abstract available
     
     
     
101. YU H, Wu H, Wang W, Jolly S, et al
     Machine Learning to Build and Validate a Model for Radiation Pneumonitis Prediction in Patients with Non-Small-Cell Lung Cancer.
     Clin Cancer Res. 2019 Apr 16. pii: 1078-0432.CCR-18-1084.
     PubMed     Abstract available
     
     
     
102. LEIGHL NB, Page RD, Raymond VM, Daniel DB, et al
     Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2019 Apr 15. pii: 1078-0432.CCR-19-0624.
     PubMed     Abstract available
     
     
     
103. MA PC
     (Not Giving Up) The Marathon Race of MET Targeting Therapy: Are We There Yet?
     Clin Cancer Res. 2019;25:2375-2378.
     PubMed     Abstract available
     
     
     
104. VAN CUTSEM E, Karaszewska B, Kang YK, Chung HC, et al
     A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.
     Clin Cancer Res. 2019;25:2414-2423.
     PubMed     Abstract available
     
     
     
105. LUSK CM, Watza D, Dyson G, Craig DB, et al
     Profiling the mutational landscape in known driver genes and novel genes in African American non-small cell lung cancer patients.
     Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-2439.
     PubMed     Abstract available
     
     
     
106. KOH J, Kim HY, Lee Y, Park IK, et al
     IL-23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3.
     Clin Cancer Res. 2019 Apr 12. pii: 1078-0432.CCR-18-3458.
     PubMed     Abstract available
     
     
     
107. VENDRELL J, Mazieres J, Senal R, Rouquette I, et al
     Ultra-sensitive EGFR (T790M)detection as an independent prognostic marker for lung cancer patients harboring EGFR (del19)mutations and treated with first-generation TKIs.
     Clin Cancer Res. 2019 Apr 1. pii: 1078-0432.CCR-18-2683.
     PubMed     Abstract available
     
     
     March 2019
108. HEIGENER DF, Kerr KM, Laing GM, Mok TSK, et al
     Redefining treatment paradigms in first-line advanced non-small cell lung cancer.
     Clin Cancer Res. 2019 Mar 25. pii: 1078-0432.CCR-18-1894.
     PubMed     Abstract available
     
     
     
109. DOROSHOW DB, Sanmamed MF, Hastings K, Politi K, et al
     Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
     Clin Cancer Res. 2019 Mar 1. pii: 1078-0432.CCR-18-1538.
     PubMed     Abstract available
     
     
     
110. PELED M, Onn A, Herbst RS
     Tumor-Infiltrating Lymphocytes-Location for Prognostic Evaluation.
     Clin Cancer Res. 2019;25:1449-1451.
     PubMed     Abstract available
     
     
     February 2019
111. JEONG MH, Park SY, Lee SH, Seo J, et al
     EPB41L5 mediates TGF--induced metastasis of gastric cancer.
     Clin Cancer Res. 2019 Feb 27. pii: 1078-0432.CCR-18-2959.
     PubMed     Abstract available
     
     
     
112. ZHANG Q, Zhang Y, Chen Y, Qian J, et al
     A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models.
     Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-2548.
     PubMed     Abstract available
     
     
     
113. TREFNY MP, Rothschild SI, Uhlenbrock F, Rieder D, et al
     A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer.
     Clin Cancer Res. 2019 Feb 14. pii: 1078-0432.CCR-18-3041.
     PubMed     Abstract available
     
     
     
114. WANG X, Liang JQ, Zhang LH, Gou H, et al
     C8orf76 promotes gastric tumorigenicity and metastasis by directly inducing lncRNA DUSP5P1 and associates with patient outcomes.
     Clin Cancer Res. 2019 Feb 7. pii: 1078-0432.CCR-18-2804.
     PubMed     Abstract available
     
     
     
115. KNORR DA, Ravetch JV
     Immunotherapy and Hyperprogression: Unwanted Outcomes, Unclear Mechanism.
     Clin Cancer Res. 2019;25:904-906.
     PubMed     Abstract available
     
     
     January 2019
116. BALTSCHUKAT S, Schacher Engstler B, Huang A, Hao HX, et al
     Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
     Clin Cancer Res. 2019 Jan 23. pii: 1078-0432.CCR-18-2814.
     PubMed     Abstract available
     
     
     
117. YUN J, Hong MH, Kim SY, Park CW, et al
     YH25448, an irreversible EGFR-TKI with Potent Intracranial Activity in EGFR mutant non-small-cell lung cancer.
     Clin Cancer Res. 2019 Jan 22. pii: 1078-0432.CCR-18-2906.
     PubMed     Abstract available
     
     
     
118. PLANCHARD D, Boyer MJ, Lee JS, Dechaphunkul A, et al
     Post-Progression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2019 Jan 18. pii: 1078-0432.CCR-18-3325.
     PubMed     Abstract available
     
     
     
119. MARTINEZ P, Peters S, Stammers T, Soria JC, et al
     Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer.
     Clin Cancer Res. 2019 Jan 14. pii: 1078-0432.CCR-18-3904.
     PubMed     Abstract available
     
     
     
120. DE GOEJE PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, et al
     Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients.
     Clin Cancer Res. 2019 Jan 14. pii: 1078-0432.CCR-18-2243.
     PubMed     Abstract available
     
     
     
121. THATCHER N, Goldschmidt JH, Thomas M, Schenker M, et al
     Efficacy & Safety of Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Non-small Cell Lung Cancer(MAPLE):A Randomized,Double-blind,Phase 3 Study.
     Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-2702.
     PubMed     Abstract available
     
     
     
122. CHEN X, Chang CW, Spoerke JM, Yoh K, et al
     Low-Pass Whole-Genome Sequencing of Circulating Cell-Free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort.
     Clin Cancer Res. 2019 Jan 7. pii: 1078-0432.CCR-18-1593.
     PubMed     Abstract available
     
     
     December 2018
123. HEYZA J, Lei W, Watza D, Zhang H, et al
     Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer.
     Clin Cancer Res. 2018 Dec 11. pii: 1078-0432.CCR-18-3094.
     PubMed     Abstract available
     
     
     
124. AKHTAR S, Meeran SM, Katiyar N, Katiyar SK, et al
     Editor's Note: Grape Seed Proanthocyanidins Inhibit the Growth of Human Non-small Cell Lung Cancer Xenografts by Targeting Insulin-Like Growth Factor Binding Protein-3, Tumor Cell Proliferation, and Angiogenic Factors.
     Clin Cancer Res. 2018;24:6101.
     PubMed    
     
     
     November 2018
125. LI L, Li W, Chen N, Zhao H, et al
     FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer.
     Clin Cancer Res. 2018 Nov 14. pii: 1078-0432.CCR-18-1447.
     PubMed     Abstract available
     
     
     
126. ESAI SELVAN M, Klein RJ, Gumus ZH
     Rare, pathogenic germline variants in Fanconi Anemia genes increase risk for squamous lung cancer.
     Clin Cancer Res. 2018 Nov 13. pii: 1078-0432.CCR-18-2660.
     PubMed     Abstract available
     
     
     October 2018
127. TAO Z, McCall NS, Wiedemann N, Vuagniaux G, et al
     SMAC mimetic Debio 1143 and ablative radiation therapy synergize to enhance anti-tumor immunity against lung cancer.
     Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-17-3852.
     PubMed     Abstract available
     
     
     
128. SUZAWA K, Offin M, Lu D, Kurzatkowski C, et al
     Activation of KRAS mediates resistance to targeted therapy in MET ex on 14 mutant non-small cell lung cancer.
     Clin Cancer Res. 2018 Oct 23. pii: 1078-0432.CCR-18-1640.
     PubMed     Abstract available
     
     
     
129. ATRAFI F, Groen HJ, Byers LA, Garralda E, et al
     A Phase 1 Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
     Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-2014.
     PubMed     Abstract available
     
     
     
130. XIE Y, Lu W, Wang S, Tang X, et al
     Validation of the 12-gene predictive signature for Adjuvant Chemotherapy Response in Lung Cancer.
     Clin Cancer Res. 2018 Oct 4. pii: 1078-0432.CCR-17-2543.
     PubMed     Abstract available
     
     
     September 2018
131. DAGOGO-JACK I, Martinez P, Yeap BY, Ambrogio C, et al
     Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-Mutant Lung Cancer.
     Clin Cancer Res. 2018 Sep 17. pii: 1078-0432.CCR-18-2062.
     PubMed     Abstract available
     
     
     
132. LO RUSSO G, Moro M, Sommariva M, Cancila V, et al
     Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-Small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.
     Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1390.
     PubMed     Abstract available
     
     
     
133. PETERS S, Stahel RA, Bubendorf L, Bonomi P, et al
     Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers.
     Clin Cancer Res. 2018 Sep 11. pii: 1078-0432.CCR-18-1590.
     PubMed     Abstract available
     
     
     
134. CORREDOR G, Wang X, Zhou Y, Lu C, et al
     Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non-small cell lung cancer.
     Clin Cancer Res. 2018 Sep 10. pii: 1078-0432.CCR-18-2013.
     PubMed     Abstract available
     
     
     August 2018
135. RICHARD C, Fumet JD, Chevrier S, Derangere V, et al
     Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.
     Clin Cancer Res. 2018 Aug 28. pii: 1078-0432.CCR-18-1940.
     PubMed     Abstract available
     
     
     
136. PINE SR
     Rethinking gamma-secretase inhibitors for treatment of non-small cell lung cancer: Is Notch the target?
     Clin Cancer Res. 2018 Aug 13. pii: 1078-0432.CCR-18-1635.
     PubMed     Abstract available
     
     
     
137. SONG KA, Hosono Y, Turner C, Jacob S, et al
     Increased synthesis of MCL-1 protein underlies initial survival of EGFR mutant lung cancer to EGFR inhibitors and provides a novel drug target.
     Clin Cancer Res. 2018 Aug 7. pii: 1078-0432.CCR-18-0304.
     PubMed     Abstract available
     
     
     
138. KIM ES, Kelly K, Paz-Ares L, Garrido P, et al
     Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study.
     Clin Cancer Res. 2018 Aug 6. pii: 1078-0432.CCR-18-0651.
     PubMed     Abstract available
     
     
     
139. BAHCALL M, Awad MM, Sholl LM, Wilson FH, et al
     Amplification of wild type KRAS imparts resistance to crizotinib in MET exon 14 mutant non-small cell lung cancer.
     Clin Cancer Res. 2018 Aug 2. pii: 1078-0432.CCR-18-0876.
     PubMed     Abstract available
     
     
     
140. WANG Y, Li N, Jiang W, Deng W, et al
     Mutant LKB1 confers enhanced radiosensitization in combination with trametinib in KRAS-mutant non-small cell lung cancer.
     Clin Cancer Res. 2018 Aug 1. pii: 1078-0432.CCR-18-1489.
     PubMed     Abstract available
     
     
     July 2018
141. PONATH P, Menezes DL, Pan C, Chen B, et al
     A novel, fully human anti-fucosyl-GM1 antibody demonstrates potent in vitro and in vivo antitumor activity in preclinical models of small cell lung cancer.
     Clin Cancer Res. 2018 Jul 18. pii: 1078-0432.CCR-18-0018.
     PubMed     Abstract available
     
     
     
142. AKIBA T, Morikawa T, Odaka M, Nakada T, et al
     Vitamin D supplementation and survival of patients with non-small-cell lung cancer: A randomized, double-blind, placebo-controlled trial.
     Clin Cancer Res. 2018 Jul 17. pii: 1078-0432.CCR-18-0483.
     PubMed     Abstract available
     
     
     
143. ROMANIELLO D, Mazzeo L, Mancini M, Marrocco I, et al
     A Combination Of Approved Antibodies Overcomes Resistance Of Lung Cancer To Osimertinib By Blocking Bypass Pathways.
     Clin Cancer Res. 2018 Jul 2. pii: 1078-0432.CCR-18-0450.
     PubMed     Abstract available
     
     
     June 2018
144. LI S, Liu S, Deng J, Akbay EA, et al
     Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer.
     Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3438.
     PubMed     Abstract available
     
     
     
145. KO EC, Raben D, Formenti SC
     The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-17-3620.
     PubMed     Abstract available
     
     
     
146. LAIRD JH, Lok BH, Ma J, Bell A, et al
     Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
     Clin Cancer Res. 2018 Jun 26. pii: 1078-0432.CCR-18-0401.
     PubMed     Abstract available
     
     
     
147. LALLO A, Frese KK, Morrow C, Szczepaniak Sloane R, et al
     The combination of the PARP inhibitor olaparib and the Wee1 inhibitor AZD1775 as a new therapeutic option for small cell lung cancer.
     Clin Cancer Res. 2018 Jun 25. pii: 1078-0432.CCR-17-2805.
     PubMed     Abstract available
     
     
     
148. SAIGI M, Alburquerque-Bejar JJ, McLEER-Florin A, Pereira C, et al
     MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer.
     Clin Cancer Res. 2018 Jun 13. pii: 1078-0432.CCR-18-0267.
     PubMed     Abstract available
     
     
     May 2018
149. BAUML J, Levy B
     Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer.
     Clin Cancer Res. 2018 May 10. pii: 1078-0432.CCR-18-0969.
     PubMed     Abstract available
     
     
     
150. HIGGS BW, Morehouse C, Streicher KL, Brohawn P, et al
     Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non-Small-Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab.
     Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3451.
     PubMed     Abstract available
     
     
     
151. NAZ S, Sowers AL, Choudhuri R, Wissler MF, et al
     Abemaciclib, a Selective CDK4/6 Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in vitro and in vivo.
     Clin Cancer Res. 2018 May 1. pii: 1078-0432.CCR-17-3575.
     PubMed     Abstract available
     
     
     April 2018
152. CLARET L, Jin JY, Ferte C, Winter H, et al
     A model of overall survival predicts treatment outcomes with atezolizumab vs chemotherapy in non-small cell lung cancer based on early tumor kinetics.
     Clin Cancer Res. 2018 Apr 23. pii: 1078-0432.CCR-17-3662.
     PubMed     Abstract available
     
     
     
153. MCCOACH CE, Le A, Gowan K, Jones KL, et al
     Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.
     Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2452.
     PubMed     Abstract available
     
     
     
154. IOMMELLI F, De Rosa V, Terlizzi C, Monti M, et al
     Inositol trisphosphate receptor type 3-mediated enhancement of EGFR and MET co-targeting efficacy in non-small cell lung cancer detected by 18F-fluorothymidine.
     Clin Cancer Res. 2018 Apr 4. pii: 1078-0432.CCR-17-3657.
     PubMed     Abstract available
     
     
     
155. FRANK R, Scheffler M, Merkelbach-Bruse S, Ihle MA, et al
     Clinical and pathological characteristics of KEAP1- and NFE2L2- mutated non-small cell lung carcinoma (NSCLC).
     Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-17-3416.
     PubMed     Abstract available
     
     
     March 2018
156. MCCOACH CE, Blakely CM, Banks KC, Levy BM, et al
     Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer.
     Clin Cancer Res. 2018 Mar 29. pii: 1078-0432.CCR-17-2588.
     PubMed     Abstract available
     
     
     
157. HORN L, Infante JR, Reckamp KL, Blumenshein GR, et al
     Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.
     Clin Cancer Res. 2018 Mar 21. pii: 1078-0432.CCR-17-2398.
     PubMed     Abstract available
     
     
     
158. CASTELLANOS-RIZALDOS E, Grimm DG, Tadigotla V, Hurley J, et al
     Exosome-based Detection of EGFR T790M in Plasma from Non-Small Cell Lung Cancer Patients.
     Clin Cancer Res. 2018 Mar 13. pii: 1078-0432.CCR-17-3369.
     PubMed     Abstract available
     
     
     
159. YANG Z, Yang N, Ou Q, Xiang Y, et al
     Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
     Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-2310.
     PubMed     Abstract available
     
     
     
160. CAPPUZZO F, Landi L
     HER2 deregulation in lung cancer: right time to adopt an orphan?
     Clin Cancer Res. 2018 Mar 1. pii: 1078-0432.CCR-18-0198.
     PubMed     Abstract available
     
     
     February 2018
161. BILLATOS E, Vick JL, Lenburg ME, Spira AE, et al
     The Airway Transcriptome as a Biomarker for Early Lung Cancer Detection.
     Clin Cancer Res. 2018 Feb 20. pii: 1078-0432.CCR-16-3187.
     PubMed     Abstract available
     
     
     
162. TIAN Y, Wang Z, Liu X, Duan J, et al
     Prediction of chemotherapeutic efficacy in non-small cell lung cancer by serum metabolomic profiling.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-2855.
     PubMed     Abstract available
     
     
     
163. YU J, Wang S, Zhao W, Duan J, et al
     Mechanistic exploration of cancer stem cell marker voltage-dependent calcium channel alpha2delta1 subunit-mediated chemotherapy resistance in small cell lung cancer.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-1932.
     PubMed     Abstract available
     
     
     
164. MACLEOD AK, Lin, Huang JT, McLaughlin LA, et al
     Identification of novel pathways of osimertinib disposition and potential implications for the outcome of lung cancer therapy.
     Clin Cancer Res. 2018 Feb 6. pii: 1078-0432.CCR-17-3555.
     PubMed     Abstract available
     
     
     January 2018
165. MCCALL NS, Dicker AP, Lu B
     Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer.
     Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3269.
     PubMed     Abstract available
     
     
     
166. KITAJIMA S, Barbie DA
     RASA1/NF1 mutant lung cancer: Racing to the clinic?
     Clin Cancer Res. 2018 Jan 17. pii: 1078-0432.CCR-17-3597.
     PubMed     Abstract available
     
     
     
167. GOLDBERG SB, Narayan A, Kole AJ, Decker RH, et al
     Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA.
     Clin Cancer Res. 2018 Jan 12. pii: 1078-0432.CCR-17-1341.
     PubMed     Abstract available
     
     
     
168. THANGAVEL C, Boopathi E, Liu Y, McNair C, et al
     Therapeutic Challenge With a CDK 4/6 Inhibitor Induces an RB-dependent SMAC Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2018 Jan 8. pii: 1078-0432.CCR-17-2074.
     PubMed     Abstract available
     
     
     
169. LIU S, Li S, Hai J, Wang X, et al
     Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.
     Clin Cancer Res. 2018 Jan 3. pii: 1078-0432.CCR-17-1875.
     PubMed     Abstract available
     
     
     December 2017
170. YE M, Zhang Y, Gao H, Xu Y, et al
     Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small-Cell Lung Cancer by Activating Src-Mediated Bypass Signaling.
     Clin Cancer Res. 2017 Dec 11. pii: 1078-0432.CCR-17-0396.
     PubMed     Abstract available
     
     
     
171. AISNER DL, Sholl LM, Berry L, Rossi M, et al
     The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).
     Clin Cancer Res. 2017 Dec 7. pii: 1078-0432.CCR-17-2289.
     PubMed     Abstract available
     
     
     
172. WANG Q, Zeng F, Sun Y, Qiu Q, et al
     Etk interaction with PFKFB4 modulates chemoresistance of small cell lung cancer by regulating autophagy.
     Clin Cancer Res. 2017 Dec 5. pii: 1078-0432.CCR-17-1475.
     PubMed     Abstract available
     
     
     
173. VILLARROEL-ESPINDOLA F, Yu X, Datar I, Mani N, et al
     Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer.
     Clin Cancer Res. 2017 Dec 4. pii: 1078-0432.CCR-17-2542.
     PubMed     Abstract available
     
     
     October 2017
174. ARBOUR KC, Jordan EJ, Kim HR, Dienstag J, et al
     Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer.
     Clin Cancer Res. 2017 Oct 31. pii: clincanres.1841.2017.
     PubMed     Abstract available
     
     
     
175. FABER AC, Song KA, Niederst MJ, Lochmann TL, et al
     Epithelial-to-mesenchymal transition antagonizes response to targeted therapies in lung cancer by suppressing BIM.
     Clin Cancer Res. 2017 Oct 19. pii: clincanres.1577.2017.
     PubMed     Abstract available
     
     
     
176. FAN Y, Zhu X, Xu Y, Lu X, et al
     Cell-cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer.
     Clin Cancer Res. 2017 Oct 13. pii: clincanres.1582.2017.
     PubMed     Abstract available
     
     
     
177. WANG Y, Gudikote J, Giri U, Yan J, et al
     RAD50 expression is associated with poor clinical outcomes after radiotherapy for resected non-small cell lung cancer.
     Clin Cancer Res. 2017 Oct 13. pii: clincanres.1455.2017.
     PubMed     Abstract available
     
     
     
178. LOHAVANICHBUTR P, Sakoda LC, Amos CI, Arnold SM, et al
     Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium.
     Clin Cancer Res. 2017 Oct 3. pii: clincanres.1401.2017.
     PubMed     Abstract available
     
     
     September 2017
179. HU X, Liu T, Wu X, Chen T, et al
     Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/beta-catenin signaling.
     Clin Cancer Res. 2017 Sep 28. pii: clincanres.1169.2017.
     PubMed     Abstract available
     
     
     
180. YI JS, Ready N, Healy P, Dumbauld C, et al
     Immune Activation in Early Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.
     Clin Cancer Res. 2017 Sep 26. pii: clincanres.2005.2017.
     PubMed     Abstract available
     
     
     
181. FENG Y, Wang X, Bajaj G, Agrawal S, et al
     Nivolumab Exposure-Response Analyses of Efficacy and Safety in Previously Treated Squamous or Nonsquamous Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2017;23:5394-5405.
     PubMed     Abstract available
     
     
     
182. GU L, Deng JZ, Roy S, Hammond PT, et al
     A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-small Cell Lung Cancer.
     Clin Cancer Res. 2017 Sep 14. pii: clincanres.2186.2016.
     PubMed     Abstract available
     
     
     August 2017
183. OOKI A, Maleki Z, Tsay JJ, Goparaju CM, et al
     A panel of novel detection and prognostic methylated DNA markers in primary non-small cell lung cancer and serum DNA.
     Clin Cancer Res. 2017 Aug 29. pii: clincanres.1222.2017.
     PubMed     Abstract available
     
     
     
184. 
     Retraction: Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216.
     Clin Cancer Res. 2017;23:4523.
     PubMed    
     
     
     
185. ENGSTROM L, Aranda R, Lee M, Tovar EA, et al
     Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-Mediated Resistance to Type I MET Inhibitors in Nonclinical Models.
     Clin Cancer Res. 2017 Aug 1. pii: clincanres.1192.2017.
     PubMed     Abstract available
     
     
     July 2017
186. SEN T, Tong P, Diao L, Li L, et al
     Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small cell lung cancer.
     Clin Cancer Res. 2017 Jul 11. pii: clincanres.1284.2017.
     PubMed     Abstract available
     
     
     
187. GRAY JE, Heist RS, Starodub AN, Camidge DR, et al
     Therapy of Small-cell Lung Cancer (SCLC) With a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan.
     Clin Cancer Res. 2017 Jul 5. pii: clincanres.0933.2017.
     PubMed     Abstract available
     
     
     
188. NISHINO M, Dahlberg SE, Adeni AE, Lydon C, et al
     Tumor response dynamics of advanced non-small-cell lung cancer patients treated with PD-1 inhibitors: Imaging markers for treatment outcome.
     Clin Cancer Res. 2017 Jul 5. pii: clincanres.1434.2017.
     PubMed     Abstract available
     
     
     
189. ADAMS DL, Adams DK, He J, Kalhor N, et al
     Sequential tracking of PD-L1 expression and RAD50 induction in circulating tumor and stromal cells of lung cancer patients undergoing radiotherapy.
     Clin Cancer Res. 2017 Jul 5. pii: clincanres.0802.2017.
     PubMed     Abstract available
     
     
     June 2017
190. MALCHERS F, Ercanoglu MS, Schutte D, Castiglione R, et al
     Mechanisms of primary drug resistance in FGFR1 amplified lung cancer.
     Clin Cancer Res. 2017 Jun 19. pii: clincanres.0478.2017.
     PubMed     Abstract available
     
     
     
191. WEINSTOCK C, Khozin S, Suzman D, Zhang L, et al
     U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer.
     Clin Cancer Res. 2017 Jun 13. pii: clincanres.0540.2017.
     PubMed     Abstract available
     
     
     
192. JIN X, Chen Y, Chen H, Fei S, et al
     Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early stage non-small-cell lung cancer using next-generation sequencing.
     Clin Cancer Res. 2017 Jun 12. pii: clincanres.0577.2017.
     PubMed     Abstract available
     
     
     May 2017
193. CASCONE T, Xu L, Lin HY, Liu W, et al
     The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer.
     Clin Cancer Res. 2017 May 30. pii: clincanres.3216.2016.
     PubMed     Abstract available
     
     
     
194. JEONG J, Oh JH, Sonke JJ, Belderbos JSA, et al
     Modeling the Cellular Response of Lung Cancer to Radiation Therapy for a Broad Range of Fractionation Schedules.
     Clin Cancer Res. 2017 May 24. pii: clincanres.3277.2017.
     PubMed     Abstract available
     
     
     
195. LEE JMM, Lee MH, Garon E, Goldman JW, et al
     Phase I trial of intratumoral injection of CCL21 gene modified dendritic cells in lung cancer elicits tumor-specific immune responses and CD8+ T cell infiltration.
     Clin Cancer Res. 2017 May 3. pii: clincanres.2821.2016.
     PubMed     Abstract available
     
     
     April 2017
196. COOPER WA, Russell PA, Cherian M, Duhig EE, et al
     Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC).
     Clin Cancer Res. 2017 Apr 18. pii: clincanres.0151.2017.
     PubMed     Abstract available
     
     
     
197. LI AN, Yang J, Zhang XC, Zhang Z, et al
     Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer.
     Clin Cancer Res. 2017 Apr 10. pii: clincanres.3273.2016.
     PubMed     Abstract available
     
     
     March 2017
198. TANG C, Welsh JW, de Groot P, Massarelli E, et al
     Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
     Clin Cancer Res. 2017;23:1388-1396.
     PubMed     Abstract available
     
     
     
199. BRANT R, Sharpe A, Liptrot T, Dry JR, et al
     Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors.
     Clin Cancer Res. 2017;23:1471-1480.
     PubMed     Abstract available
     
     
     
200. LIU Y, Balagurunathan Y, Atwater T, Antic S, et al
     Radiological Image Traits Predictive of Cancer Status in Pulmonary Nodules.
     Clin Cancer Res. 2017;23:1442-1449.
     PubMed     Abstract available
     
     
     
201. SCARBOROUGH HA, Helfrich BA, Casas-Selves M, Schuller AG, et al
     AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
     Clin Cancer Res. 2017;23:1531-1541.
     PubMed     Abstract available
     
     
     
202. KURZROCK R, Stewart DJ
     Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
     Clin Cancer Res. 2017;23:1137-1148.
     PubMed     Abstract available
     
     
     January 2017
203. DAMA E, Melocchi V, Dezi F, Pirroni S, et al
     An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
     Clin Cancer Res. 2017;23:62-72.
     PubMed     Abstract available
     
     
     July 2016
204. BALLARD P, Yates JW, Yang Z, Kim DW, et al
     Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
     Clin Cancer Res. 2016 Jul 19. pii: clincanres.0399.2015.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: